Literature DB >> 10334676

Glucocorticosteroids in the management of rheumatoid arthritis.

R F Laan1, T L Jansen, P L van Riel.   

Abstract

Glucocorticosteroids are used frequently in the management of patients with rheumatoid arthritis. Data supporting their efficacy and safety are still meagre. Glucocorticosteroids may be used systemically with different routes of administration (oral, i.m. and i.v.), in different doses and for different periods of time. The effectiveness of glucocorticosteroids in reducing inflammation in the short term has been shown for oral treatment in a dose of 7.5 mg prednisolone daily or more, for i.m. pulses (120 mg methylprednisolone every 4 weeks) and for i.v. methylprednisolone pulses. For longer periods of treatment, the evidence suggesting effectiveness of low-dose oral glucocorticosteroids is more limited. Some data suggest that different regimens of glucocorticosteroids may retard the development of erosions in patients with rheumatoid arthritis. The toxicity of short-term treatment is relatively low. For long-term treatment, the development of osteoporosis is a serious problem. Concomitant therapy with either calcitriol or bisphosphonates may reduce this risk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334676     DOI: 10.1093/rheumatology/38.1.6

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

1.  Enhanced therapeutic anti-inflammatory effect of betamethasone on topical administration with low-frequency, low-intensity (20 kHz, 100 mW/cm(2)) ultrasound exposure on carrageenan-induced arthritis in a mouse model.

Authors:  Gadi Cohen; Hiba Natsheh; Youhan Sunny; Christopher R Bawiec; Elka Touitou; Melissa A Lerman; Philip Lazarovici; Peter A Lewin
Journal:  Ultrasound Med Biol       Date:  2015-05-21       Impact factor: 2.998

2.  Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).

Authors:  Ruediger B Mueller; Nazim Reshiti; Toni Kaegi; Axel Finckh; Sarah R Haile; Hendrik Schulze-Koops; Michael Schiff; Michael Spaeth; Johannes von Kempis
Journal:  Clin Rheumatol       Date:  2016-11-12       Impact factor: 2.980

3.  [Therapeutic strategies in rheumatoid arthritis].

Authors:  H Bastian; E Feist; G-R Burmester
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

4.  A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells.

Authors:  Yee-Joo Tan; Eileen Teng; Anthony E Ting
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-16       Impact factor: 4.553

5.  The Development of Novel Therapies for Rheumatoid Arthritis.

Authors:  Ling-Dong Quan; Geoffrey M Thiele; Jun Tian; Dong Wang
Journal:  Expert Opin Ther Pat       Date:  2008-07       Impact factor: 6.674

6.  Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells.

Authors:  Aiko Ogawa; Amy L Firth; Weijuan Yao; Lewis J Rubin; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-08-15       Impact factor: 5.464

7.  Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

Authors:  Izabela Korczowska; Anna Olewicz-Gawlik; Jakub Trefler; Paweł Hrycaj; Jan Krzysztof Łacki
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

8.  Single-molecule force spectroscopy reveals folding steps associated with hormone binding and activation of the glucocorticoid receptor.

Authors:  Thomas Suren; Daniel Rutz; Patrick Mößmer; Ulrich Merkel; Johannes Buchner; Matthias Rief
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-26       Impact factor: 11.205

9.  Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.

Authors:  Jungyeon Hwang; Kathleen Rodgers; James C Oliver; Thomas Schluep
Journal:  Int J Nanomedicine       Date:  2008

10.  Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.

Authors:  Kristin Andreas; Thomas Häupl; Carsten Lübke; Jochen Ringe; Lars Morawietz; Anja Wachtel; Michael Sittinger; Christian Kaps
Journal:  Arthritis Res Ther       Date:  2009-02-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.